The South Korean biotech sector has so far missed out on the global trend of mergers and acquisitions (M&A) and technology transfers, despite positive momentum in the global pharmaceutical industry. Analysts suggest that a series of upcoming clinical results and technology transfer events in the latter half of the year could catalyze a reevaluation of Korean biotech stocks. Samsung Securities has provided an ‘OVERWEIGHT’ recommendation for the healthcare sector, highlighting major upcoming events that could influence investment sentiment. Key companies to watch include Celltrion, GC, and Yuhan Corporation, which are expected to experience significant developments. Additionally, Peptron and Kolon TissueGene are identified as having crucial milestones that could impact the biotech market in Korea. Overall, the second half of the year is seen as a potential turning point for domestic biotech stocks.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.asiae.co.kr/en/article/2026081408202722087
